Identification and uses of vasculature forming progenitor cells and progenitor cell combinations

Patent metadata

Field	Value
Publication number	US-11369641-B2
Application number	US-201716323079-A
Country	US
Kind code	B2
Filing date	Aug 25, 2017
Priority date	Aug 26, 2016
Publication date	Jun 28, 2022
Grant date	Jun 28, 2022

Abstract

Methods, compositions, and kits for producing functional blood vessels, and progenitors thereof are provided. Human disorders of the vascular system are treated by reconstitution of functional vessels in vivo through co-transplantation with supporting niche stromal cells for treatment of ischemic injury in the peripheral limbs and heart. The cell populations of the invention, when engrafted into a recipient, anastomose with host vasculature and regenerate functional blood vessels.

First claim

What is claimed is:

1. A method for generating functional blood vessels in a human individual recipient, the method comprising:
a) isolating P1 and P2 cells from human adipose stromal tissue, wherein P1 cells are defined as CD45 − Tie2 + CD105 + PDGFRα − CD31 + and P2 cells are defined as CD45 − Tie2 + CD105 + PDGFRα + CD31 − ; and
b) administering to the human individual recipient a composition comprising an effective dose of the isolated P1 and P2 cells of step (a), at a site where regeneration of vessels is desired,
wherein the isolated P1 and P2 cells are present in the composition at a ratio of 1:100 to 100:1, and
wherein the isolated P1 and P2 cells are autologous with respect to the human individual recipient.

2. The method of claim 1 , wherein the effective dose is from 10 3 to 10 10 total cells.

3. The method of claim 1 , wherein the composition is provided in a matrix.

4. A method for generating functional blood vessels in a human individual recipient, the method comprising:
a) isolating P1 and P2 cells from human adipose stromal tissue, wherein P1 cells are defined as CD45 − Tie2 + CD105 + PDGFRα − CD31 + and P2 cells are defined as CD45 − Tier CD105 + PDGFRα + CD31 − ; and
b) administering to the human individual recipient a composition comprising an effective dose of the isolated P1 and P2 cells of step (a), at a site where regeneration of vessels is desired,
wherein the isolated P1 and P2 cells are present in the composition at a ratio of 1:100 to 100:1, and
wherein the isolated P1 and P2 cells are allogeneic with respect to the human individual recipient.

5. The method of claim 1 , wherein the P1 and P2 cells are freshly isolated from lipoaspirate.

6. The method of claim 1 , wherein the P1 and P2 cells are isolated from adult human adipose stromal tissue.

7. The method of claim 1 , wherein the human individual recipient suffers from ischemic cardiovascular disease.

8. The method of 7 , wherein the human individual recipient suffers from coronary artery disease (CAD), peripheral arterial disease (PAD), or stroke.

9. A method for generating adipose tissue in a human individual recipient, the method comprising:
a) isolating P2 cells from human adipose stromal tissue, wherein P2 cells are defined as CD45 − Tier CD105 + PDGFRα + CD31 − ; and
b) administering to the human individual recipient a composition comprising an effective dose of the isolated P2 cells of step (a), at a site where regeneration of adipose tissue is desired,
wherein the isolated P2 cells are autologous with respect to the human individual recipient,
wherein the composition lacks P1 cells, and
wherein P1 cells are defined as CD45 − Tie2 + CD105 + PDGFRα 31 CD31 + .

Assignees

• Univ Leland Stanford Junior

Inventors

• Chan Charles K F
• Lee Andrew Stephen
• Longaker Michael T
• Weissman Irving L
• Wu Joseph
• Nag Divya
• Seo Eun Young

Classifications

• A61K35/28 Primary

  Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title

• A61K35/35 Primary

  Fat tissue; Adipocytes; Stromal cells; Connective tissues (adipose-derived stem cells A61K35/28; collagen A61K38/39) · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• C12N5/0667

  Adipose-derived stem cells [ADSC]; Adipose stromal stem cells · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title